Breast Cancer Solutions

Alpha Tau is a medical device company that focuses on the development and commercialization of its Diffusing Alpha-emitters Radiation Therapy (DaRT) for the treatment of solid cancers.

The technology, which was developed at Tel Aviv University in 2003, enables a highly potent and conformal radiotherapy treatment using alpha-emitting atoms. Directly inserted into the tumor, the Alpha DaRT seeds release a high-energy dose over a range of several millimeters, enabling a focal alpha-radiation treatment that spares the surrounding healthy tissue.

In 2017, Alpha Tau started with its first-in-human study of locally advanced and recurrent SCC cancers of the skin and head and neck, the results of which were subsequently published in the prestigious International Journal of Radiation Oncology | Biology | Physics. Following these initial encouraging results, Alpha Tau substantially expanded its clinical evaluations in later trials to a much wider patient population.
The supportive data from these first trials also led to the FDA granting Breakthrough Device Designation to the Alpha DaRT for the treatment of patients with SCC of the skin or oral cavity without curative standard of care. Later on, Alpha Tau also received FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM (glioblastoma multiforme).

Today, in partnership with a number of esteemed medical and educational institutions worldwide, Alpha Tau has commenced several clinical and pre-clinical studies which are presently ongoing, and is also currently evaluating other potential uses of the Alpha DaRT technology for indications such as breast, pancreas, lung, GBM and prostate cancers, as well as other applications such as combinations with immunotherapies.

Ibex Medical Analytics uses artificial intelligence technology to develop clinical-grade solutions designed to detect cancer as accurately as a human pathologist.

The companys Galen platform uses algorithms to analyze images, detect and grade cancer in biopsies, and point to other findings with high clinical importance, helping pathologists to reduce diagnostic error rates and enable a more efficient workflow.

Deployed worldwide, Ibexs Galen Prostate and Galen Breast are AI-based cancer detection solutions used in routine clinical practice in pathology labs, with demonstrated success in detecting missed cancer cases.

In addition, the company is developing computational prognostic and predictive tests that will enable enhanced patient population stratification and quicker personalized treatment selection.

IceCure is transforming healthcare with the choice of advanced minimally invasive cryoablation for benign and malignant tumors in women's health and interventional oncology. The FDA cleared and CE marked ProSense® System uses liquid-nitrogen (LN2) to generate ultra cold temperatures to destroy tumors by freezing them and is supported by clinical experience across multiple areas of cancer care.

Unlike surgical removal of a tumor, cryoablation is less invasive as only a thin, needle-like cryoprobe is placed into the tumor, no tissue is removed, and it is performed under local anesthesia or light sedation. Under imaging guidance (ultrasound or CT), LN2 enters the close-looped cryoprobe needle and a lethal ice ball forms around the targeted tissue. The destroyed tissue undergoes a necrotic process, to naturally remove the ablated cells over time, without needing to surgically remove it.

IceCure led the ICE3 clinical trial on cryoablation of early-stage, low-risk breast cancer, one of the largest studies of its kind. The ICE3 demonstrated a 96.3% recurrence-free rate for early-stage, low-risk breast cancer patients who underwent ProSense cryoablation with endocrine therapy. Patients and physicians reported a high level of satisfaction with the cosmetic results, as only a small nick is made in the skin to insert the cryoprobe and the breast remains whole. An FDA panel voted favorably on ProSense's benefit-risk profile in November 2024.

The ICESECRET study interim results for the destruction of kidney tumors has shown IceCure's ProSense® cryoablation system to be safe and effective in the destruction of kidney tumors with 88.7% recurrence-free rate.

ProSense® currently has FDA clearance for use as a cryosurgical tool in the destruction of fibroadenomas and in the fields of general surgery, thoracic surgery, gynecology, oncology, proctology, and urology. The system is CE-marked and is available across several European and East Asian countries, Brazil, and India.

EZbra Advanced Wound Care is the developer of EZbra, a patented, sterile, disposable bra for advanced postoperative wound care. EZbra addresses the difficulty and discomfort many post-op patients experience with current breast-wound dressings.
EZbra offers a tailored solution for each patient and their specific breast shape and requirements. It is an all-in-one product designed for the many needs and challenges created by breast procedures including biopsies, lumpectomies, mastectomies, reconstructions, and aesthetic procedures. EZbra is a class-1 (exempt from 510k) medical device in the United States.

EZbra was founded by Efrat Roman, a breast cancer survivor and the founder of CureDiva.com, a social commerce website for women dealing with breast cancer. The company is a women-led start-up and part of the emerging FemTech industry, which focuses on women's healthcare and wellness.

MICA AI Medical is a decision-support information hub and medical record platform for breast cancer prevention.
The company's DENISE is an AI-based algorithm that provides decision support to radiologists. DENISE was developed and validated at the Sheba Hospital and showed an increase in mammography accuracy to 90% and decreased unnecessary biopsies by 30%. DENISE is covered by US Patent No. 10,499,866.
The company's Mammography Image Comparison Analysis (MICA) shows suspicious new changes in mammograms over time, using MICA's artificial intelligence and machine-learning algorithms.

MICA's app allows users to manage medical records, images, and second opinions. It offers unlimited storage for mammography images, MRIs, ultrasounds, biopsies, BIRADS scores, etc.
The company's technology is sensitive to breast masses in pregnant, young, lactating, and elderly women. It can also compare current mammograms to prior studies, facilitating follow-up for patients with known lesions.

CureDiva is a high-end shopping and community platform that addresses the lifestyle needs of women at every phase of breast cancer treatment.

CureDivas product-discovery platform exposes users to stylish products and solutions, while its blog network connects them with a dedicated community of peers from whom they can receive comfort and advice.

NUTEK takes part in the fight against cancer by pioneering precision in Surgical Oncology. NUTEK is addressing the problem of cancer tissues that remain undetected on the patient's body after surgical intervention, which is the main cause of subsequent cancer recurrence, repeated operations, and aggressive treatments. Furthermore, the resulting economic burden on hospitals, healthcare organizations insurance companies is significantly high.

NUTEK provides a unique intraoperative solution, the "Rainbow Probe".
A high-resolution hyperspectral imaging handheld device, by which surgeons will scan the operation cavity on-the-patient’s-body during surgery. The probe guides the surgeon prior to closing, to the exact location of remaining cancer tissue, which otherwise could remain undetected, for immediate removal.

Conceptual video :
https://youtu.be/bcrlMbuwTJA

Its first application is Breast Cancer, for which the NOAM Rainbow Probe is developed, to be followed with addressing high-precision and minimally invasive, cancer surgical interventions. .

NUTEK won first prize at Paul Merage Institute startup competition and received a major non-dilutive grant from the FFG (Austrian Innovation Authority) for a two years project.
NUTEK is collaborating with the Medical University of Graz in Austria and with Assuta Ashdod Hospital in Israel, completed pre-clinical experiment on breast cancer, developed MVP (TRL6) and designed critical parts of the end-product.

NUTEK is currently fundraising. Join us on our life-saving mission.

Feminai's mission is to provide women efficient and safe means to detect early breast cancer. Feminai's solution is a home breast cancer screening device combined with a personalized AI-based medical screening plan.

Cintec Medical manufactures mammography and biopsy systems for the early detection of breast cancer. Focused on the needs of its users, research at Cintec is dynamic and market driven, enabling the company to respond rapidly to the changing requirements of mammography and healthcare in general.

Fixnip is a medical device start-up that develops a line of hypodermic silicone nipple implants. The company's solution allows women to regain their self-confidence and attain attractive results when undergoing post-mastectomy breast reconstruction, repair of inverted nipples, or nipple enhancement for aesthetic reasons.

Combining precise laser cutting, cast molding, and clean room technology with advanced materials such as Nitinol and soft medical silicone, the product feels real to the touch while maintaining its structure in the long term. In addition, insertion of the Fixnip implant requires a minimally invasive procedure that can be carried out in an outpatient setting in less than 20 minutes.

Fixnip's patented Nitinol skeleton combined with the soft medical silicone casting allows the product to maintain mechanical strength and guarantees a consistent, dependable structure that is simultaneously soft, flexible, and natural in look and feel.

BioXL is a biopharma company focused on developing innovative solutions for critical and underserved medical conditions.
Our pivotal portfolio projects include:
CancerPredict: a diagnostic test, based on biomarker, aims to predict breast cancer development. The test planned to be integrated in the current screening program, and will be carried out by authorized labs. Product includes proprietary testing kit and AI-powered software. The project received grant from IIA (Israel Innovation Authority)
CeaseCancer,: an anti-cancer biologic drug for Pancreatic cancer treatment. The product is an injectable (i.v or S.C) where the drug substance (API) is a human-recombinant version of a naturally expressed regulatory protein, having tumor suppression activity in the human body. The API has a unique MoA, affecting only cancer cells and does not harm normal cells. Efficacy and safety demonstrated in vitro and in animal models. Synergy was demonstrated with chemotherapy. The intended treatment is monotherapy or in combination with other treatments (i.e chemo or radiation)., as first line treatment or second line, where other therapies are not effective, i.e, in cases of cancer recurrence, resistant to chemotherapy.
NES Pharma: drug treatment to prevent or slow dementia progression. The drug combines drug substances targeting glutamate excitotoxicity, with different MoAs, enabling efficacy with minimal adverse effects. The drug intended for subscription to people diagnosed at MCI (Mild Cognitive Impairment) or people at high risk to develop dementia.
Other projects: AMP-Bio (antimicrobial drug to treat multi-drug resistant pathogens) and Marathon (delivery for use in MRT (Mitochondrial Replacement therapy))

Sebana Medical specializes in the development, manufacturing, and commercialization of cutting-edge products utilizing a proprietary platform SEBA. Its advanced Biologic Matrix Slow-Release Technology revolutionizes the delivery of a therapeutic solution, ensuring optimal efficacy and long-lasting effects of autologous fat grafts.
​
SEBA is indicated for treating fat grafts for dermal filling. Sebana Medical ambition is to prove the efficacy and commercialize SEBA for dermal filling with autologous fat.

Sebana Medical has successfully demonstrated the safety and efficacy of SEBA in rigorous preclinical studies, paving the way for its transition to clinical trials. By harnessing the power of advanced drug slow-release polymer technology, scientific expertise, and development, it has achieved a breakthrough innovation that holds immense potential.
Its technology prevents fat resorption in soft tissue augmentation and extends to various cosmetic indications.

SynergyMed is an early stage start-up company developing medical devices for cancer treatment in human and veterinary applications. The companys noninvasive solution is designed to replace the surgical resection of cancerous tumors with a system that quickly and effectively ablates and destroys tumors without damaging healthy tissue.

Medlife specializes in customizing, developing, and implementing solutions for the medical industry. The company develops a broad range of products, including its smart fetal monitoring solution HOBar. Medlife also provides custom software solutions for a wide variety of devices and medical fields.